EVMN— Evommune, Inc.

Evommune's Chronic-Hives Drug May See Wider Use If Trial Succeeds, RBC Says

Biotech’s IPO comeback; Trump’s tariff loophole for pharma

Evommune bucked biotech IPO drought and is focused on the long game

Evommune to Host KOL Webinar on April 13, 2026 Highlighting the Potential of MRGPRX2 Inhibition in Migraine

Apogee strengthens case for longer-lasting eczema drug

Evommune Stock Sees RS Rating Rise To 91

Evommune raises $125M privately

Evommune's EVO301 Phase 2a Data Drives 70% Stock Surge